| [1] Norgren L, Hiatt WR, Dormandy JA,et al. Inter-society consensus for the management of peripheral arterial disease(TASC II). Eur J Vasc Endovasc Surg.2007;33(Suppl 1):S1-S75.[2] Casserly IP. Interventional management of critical limb ischemia in renal patients. Adv Chronic Kidney Dis. 2008; 15(4):384-395.[3] Ubbink DT, Vermeulen H. Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. Cochrane Database Syst Rev. 2013;2:CD004001.[4] Dohmen A, Eder S, Euringer W, et al. Chronic critical limb ischemia. Dtsch Arztebl Int. 2012;109(6):95-101. [5] Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006;47(6):1239-1312. [6] Hooi JD, Kester AD, Stoffers HE, et al. Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study. J Clin Epidemiol. 2004;57(3):294-300.[7] Tateno K, Minamino T, Toko H, et al. Critical roles of muscle-secreted angiogenic factors in therapeutic neovascularization. Circ Res. 2006;98(9):1194-1202. [8] Collinson DJ, Donnelly R. Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation? Eur J Vasc Endovasc Surg. 2004;28(1):9-23.[9] Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Circ Res. 2007;100(9):1249-1260. [10] Barrilleaux B, Phinney DG, Prockop DJ, et al. Review: ex vivo engineering of living tissues with adult stem cells. Tissue Eng. 2006;12(11):3007-3019. [11] Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275(5302):964-967.[12] Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360(9331): 427-435. [13] Ruifrok WP, de Boer RA, Iwakura A, et al. Estradiol-induced, endothelial progenitor cell-mediated neovascularization in male mice with hind-limb ischemia. Vasc Med. 2009;14(1): 29-36. [14] Li M, Zhou H, Jin X, et al. Autologous Bone Marrow Mononuclear Cells Transplant in Patients With Critical Leg Ischemia: Preliminary Clinical Results. Exp Clin Transplant. 2013 Mar 11.[15] Subrammaniyan R, Amalorpavanathan J, Shankar R, et al. Application of autologous bone marrow mononuclear cells in six patients with advanced chronic critical limb ischemia as a result of diabetes: our experience. Cytotherapy. 2011;13(8): 993-999.[16] Murphy MP, Lawson JH, Rapp BM, et al. Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia. J Vasc Surg. 2011;53(6):1565-1574.[17] Jonsson TB, Larzon T, Arfvidsson B, et al. . Adverse events during treatment of critical limb ischemia with autologous peripheral blood mononuclear cell implant. Int Angiol .2012; 31(1):77-84.[18] Lin MN, Shang DS, Sun W, et al. Involvement of PI3K and ROCK signaling pathways in migration of bone marrow-derived mesenchymal stem cells through human brain microvascular endothelial cell monolayers. Brain Res. 2013;1513:1-8.[19] Saigawa T, Kato K, Ozawa T, et al. Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone marrow cells. Circ J. 2004;68(12): 1189-1193. [20] Rookmaaker MB, Verhaar MC, Loomans CJ, et al. CD34+ cells home, proliferate, and participate in capillary formation, and in combination with CD34- cells enhance tube formation in a 3-dimensional matrix. Arterioscler Thromb Vasc Biol. 2005; 25(9):1843-1850. [21] Losordo DW, Kibbe MR, Mendelsohn F, et al. Autologous CD34+ Cell Therapy for Critical Limb Ischemia Investigators. Circ Cardiovasc Interv. 2012;5(6):821-830.[22] Stec M, Baran J, Szatanek R, et al. Interactions of monocyte subpopulations generated from cord blood CD34(+) hematopoietic progenitors with tumor cells: assessment of antitumor potential. Exp Hematol. 2012;40(11):914-921. [23] Fernandez Pujol B, Lucibello FC, Gehling UM, et al. Endothelial-like cells derived from human CD14 positive monocytes. Differentiation. 2000;65(5):287-300. [24] Iba O, Matsubara H, Nozawa Y, et al. Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs. Circulation. 2002;106(15): 2019-2025. [25] Zhang YY, Yue J, Che H, et al. BKCa and hEag1 channels regulate cell proliferation and differentiation in human bone marrow-derived mesenchymal stem cells. J Cell Physiol. 2013 Jul 23.[26] Heil M, Ziegelhoeffer T, Mees B, et al. A different outlook on the role of bone marrow stem cells in vascular growth: bone marrow delivers software not hardware. Circ Res. 2004;94(5): 573-574. [27] Shen WC, Liang CJ, Wu VC, et al.Endothelial progenitor cells derived from Wharton's jelly of the umbilical cord reduces ischemia-induced hind limb injury in diabetic mice by inducing HIF-1α/IL-8 expression.Stem Cells Dev. 2013;22(9):1408- 1418. [28] Yang XF, Wu YX, Wang HM, et al. Autologous peripheral blood stem cells transplantation in treatment of 62 cases of lower extremity ischemic disorder. Zhonghua Nei Ke Za Zhi. 2005;44(2):95-98. [29] Tsukada S, Kwon SM, Matsuda T, et al. Identification of mouse colony forming endothelial progenitor cells for postnatal neovascularization: a novel insight highlighted by new mouse colony forming assay. Stem Cell Res Ther. 2013; 4(1):20.[30] López M, San Román J, Estrada V, et al. Endothelial dysfunction in HIV infection--the role of circulating endothelial cells, microparticles, endothelial progenitor cells and macrophages. AIDS Rev. 2012;14(4):223-230. [31] Honold J, Lehmann R, Heeschen C, et al. Effects of granulocyte colony simulating factor on functional activities of endothelial progenitor cells in patients with chronic ischemic heart disease. Arterioscler Thromb Vasc Biol. 2006;26(10): 2238-2243. [32] Dubsky M, Jirkovska A, Bem R, et al. Both autologous bone marrow mononuclear cells and peripheral blood progenitor cells therapies similarly improve ischemia in patients with diabetic foot in comparison with control treatment.Diabetes Metab Res Rev. 2013 Feb 7.[33] Mohammadzadeh L, Samedanifard SH, Keshavarzi A, et al. Therapeutic outcomes of transplanting autologous granulocyte colony-stimulating factor-mobilised peripheral mononuclear cells in diabetic patients with critical limb ischaemia. Exp Clin Endocrinol Diabetes. 2013;121(1):48-53.[34] Seeger FH, Tonn T, Krzossok N, et al. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J. 2007;28(6):766-772. [35] Bartsch T, Falke T, Brehm M, et al. Intra-arterial and intramuscular transplantation of adult, autologous bone marrow stem cells. Novel treatment for therapy-refractory peripheral arterial occlusive disease. Dtsch Med Wochenschr. 2006;131(3):79-83. [36] Iso Y, Soda T, Sato T, et al. Impact of implanted bone marrow progenitor cell composition on limb salvage after cell implantation in patients with critical limb ischemia. Atherosclerosis. 2010;209(1):167-172.[37] Klepanec A, Mistrik M, Altaner C, et al. No difference in intra-arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplant. 2012;21(9):1909-1918.[38] Keller LH.Bone marrow-derived aldehyde dehydrogenase-bright stem and progenitor cells for ischemic repair. Congest Heart Fail. 2009;15(4):202-206.[39] Perin EC, Silva G, Gahremanpour A, et al. A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia.Catheter Cardiovasc Interv. 2011;78(7):1060-1067.[40] Wang P, Luo Y, Duan H, et al. MicroRNA-329 suppresses angiogenesis by targeting CD146. Mol Cell Biol. 2013.[41] Powell RJ, Comerota AJ, Berceli SA, et al. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia. J Vasc Surg. 2011;54(4): 1032-1041.[42] Schiavetta A, Maione C, Botti C, et al.A phase II trial of autologous transplantation of bone marrow stem cells for critical limb ischemia: results of the Naples and Pietra Ligure Evaluation of Stem Cells study.Stem Cells Transl Med. 2012; 1(7):572-578.[43] Mamidi MK, Pal R, Dey S, et al.Cell therapy in critical limb ischemia: current developments and future progress. Cytotherapy. 2012;14(8):902-916.[44] Smadja DM, Duong-van-Huyen JP, Dal Cortivo L, et al.Early endothelial progenitor cells in bone marrow are a biomarker of cell therapy success in patients with critical limb ischemia. Cytotherapy. 2012;14(2):232-239. [45] Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26(3):517-538. [46] Lasala GP, Silva JA, Minguell JJ. Therapeutic angiogenesis in patients with severe limb ischemia by transplantation of a combination stem cell product. J Thorac Cardiovasc Surg. 2012;144(2):377-382. [47] Das AK, Bin Abdullah BJ, Dhillon SS, et al. Intra-arterial allogeneic mesenchymal stem cells for critical limb ischemia are safe and efficacious: report of a phase I study. World J Surg. 2013;37(4):915-922. |
